Incretin-based therapies in 2021 – Current status and perspectives for the future

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action

(2021) Francesco Maranta et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

(2021) Michael A. Nauck et al.   Frontiers in Endocrinology

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

(2021) Julio Rosenstock et al.   LANCET

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

(2021) Hertzel C. Gerstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 and diabetes management: What should be considered?

(2020) Antonio Ceriello et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management

(2020) Anca Pantea Stoian et al.   Metabolic Syndrome and Related Disorders

COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next

(2020) Angeliki M. Angelidi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Issues for the management of people with diabetes and COVID-19 in ICU

(2020) Antonio Ceriello et al.   Cardiovascular Diabetology

Diabetes and COVID-19: IDF perspective in the Western Pacific region

(2020) Yerin Hwang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

(2020) Anca Pantea Stoian et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

(2020) Anca Pantea Stoian et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?

(2020) Melanie J. Davies et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Commentary: COVID-19 in patients with diabetes

(2020) Michael A. Hill et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

(2020) Guntram Schernthaner et al.   Cardiovascular Diabetology

COVID-19 in people living with diabetes: An international consensus

(2020) A.E. Caballero et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

(2020) Alexandros Sachinidis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect

(2020) Dragana Nikolic et al.   Diabetes Therapy

Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa

(2020) Francesco Giorgino et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel

(2020) Maciej Banach et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The incretin system in healthy humans: The role of GIP and GLP-1

(2019) Jens Juul Holst   METABOLISM-CLINICAL AND EXPERIMENTAL

Of mice and men: incretin actions in the central nervous system

(2019) Olivia M. Farr et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin

(2019) Anastasia-Stefania Alexopoulos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes

(2019) Johan Farngren et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?

(2019) Alexander Kokkinos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship

(2019) Michael A. Nauck   METABOLISM-CLINICAL AND EXPERIMENTAL

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2019) Søren L Kristensen et al.   Lancet Diabetes & Endocrinology

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure

(2019) Francesco Giorgino et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Incretin-based therapies: where will we be 50 years from now?

(2015) Juris J. Meier et al.   DIABETOLOGIA

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE